Skip to content

RANDOMISED EVALUATION OF COVID-19 THERAPY (RECOVERY)

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2023-507441-29-00
Enrollment
1590
Registered
2024-02-02
Start date
2024-02-29
Completion date
Unknown
Last updated
2025-11-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pneumonia

Brief summary

28 day all-cause mortality, Time to discharge alive from hospital within 28 days (patients with influenza only)

Detailed description

Time to discharge alive from hospital within 28 days (patients without influenza), Progression to invasive mechanical ventilation (including extracorporeal membrane oxygenation) or death within 28 days

Interventions

Sponsors

University Of Oxford
Lead SponsorOTHER

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Design outcomes

Primary

MeasureTime frame
28 day all-cause mortality, Time to discharge alive from hospital within 28 days (patients with influenza only)

Secondary

MeasureTime frame
Time to discharge alive from hospital within 28 days (patients without influenza), Progression to invasive mechanical ventilation (including extracorporeal membrane oxygenation) or death within 28 days

Countries

Belgium, Estonia, France, Italy, Netherlands, Portugal, Romania, Spain, Sweden

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026